AXSM Axsome Therapeutics (AXSM) Q2 FY26 earnings call
Axsome Therapeutics delivered strong Q2 FY26 results, driven by robust commercial performance of Auvelity and Sunosi, alongside significant pipeline progress. The launch of Auvelity for Alzheimer's disease agitation shows promising early uptake, supported by an expanded sales force. The company remains focused on advancing its neuroscience pipeline with multiple late-stage candidates and maintaining a strong financial position to fund future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
AXSM operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| New prescribers activated AUVELITY | 5,500+Additionally, more than 5,500 new prescribers were activated in the quarter, bringing the total number of unique prescribers for AUVELITY since launch to approximately 60,000.Source: earnings call transcript | 6,800+In addition to accelerated new patient starts, the expanded sales force activated more than 6,800 new Auvelity prescribers in the quarter, representing 21% growth versus the previous quarter, bringing the total number of unique prescribers since launch to approximately 69,000.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.